About Eidos Therapeutics
Eidos Therapeutics is a company based in Palo Alto (United States) founded in 2016 by Isabella Graef, Neil Kumar, and Mamoun Alhamadsheh was acquired by BridgeBio in October 2020. Eidos Therapeutics has raised $64 million across 1 funding round from investors including BridgeBio, Janus Henderson Investors and RA Capital. Eidos Therapeutics offers products and services including Attruby and Nulibry. Eidos Therapeutics operates in a competitive market with competitors including BridgeBio, Moderna, Spark Therapeutics, Mereo BioPharma and Amicus Therapeutics, among others.
- Headquarter Palo Alto, United States
- Founders Isabella Graef, Neil Kumar, Mamoun Alhamadsheh
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Bridgebio Pharma, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Eidos Therapeutics
Eidos Therapeutics offers a comprehensive portfolio of products and services, including Attruby and Nulibry.
Approved drug for treating specific genetic diseases effectively.
Medicine targeting genetic conditions to improve patient outcomes.
People of Eidos Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Eidos Therapeutics
Eidos Therapeutics has successfully raised a total of $64M through 1 strategic funding round. The most recent funding activity was a Series B round of $64 million completed in April 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Eidos Therapeutics
Eidos Therapeutics has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include BridgeBio, Janus Henderson Investors and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple sectors are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
Private investment firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
PE firm investing in the US
|
Locked | Locked | Locked |
Investor details for Eidos Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Eidos Therapeutics
Investment portfolio details for Eidos Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Eidos Therapeutics
Detailed financials for Eidos Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Eidos Therapeutics Comparisons
Peer comparison for Eidos Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Eidos Therapeutics
Eidos Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Moderna, Spark Therapeutics, Mereo BioPharma and Amicus Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of therapies for rare and orphan diseases
|
|
| Locked | Locked | Locked |
Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases
|
Detailed competitors of Eidos Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Eidos Therapeutics
Complete news archive for Eidos Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Eidos Therapeutics
Eidos Therapeutics was founded in 2016 and raised its 1st funding round 2 years after it was founded.
Eidos Therapeutics is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
Neil Kumar is the current CEO of Eidos Therapeutics. They have also founded this company.
Eidos Therapeutics is a funded company, having raised a total of $64M across 1 funding round to date.
Eidos Therapeutics was founded in 2016 in Palo Alto, United States, as a biotechnology firm focused on rare diseases. Small-molecule therapies are developed to address transthyretin (TTR) amyloidosis, with the lead candidate AG10 designed to stabilize TTR proteins and inhibit amyloid formation. Both hereditary and wild-type forms of the disease are targeted through these operations, which emphasize clinical advancement in the therapeutic sector.
Eidos Therapeutics's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Eidos Therapeutics offers Attruby and Nulibry.
Eidos Therapeutics has 8 investors. Key investors include BridgeBio, Janus Henderson Investors, RA Capital, Perceptive Advisors, and Viking Global Investors.